NF-κB and NLRP3 gene expression changes during warm hepatic ischemia-reperfusion in rats with and without silibinin
Gastroenterology and Hepatology from Bed to Bench,
26 April 2021
Hepatic ischemia-reperfusion (I/R) is a common phenomenon in many clinical cases, including liver surgery and transplantation. Inflammatory mediators are vital contributors to the expansion of hepatic damages after I/R injury (I/RI), and therefore, targeting inflammation is a considerable candidate for the management of hepatic I/RI and its complications. This research examined silibinin's anti-inflammatory outcomes on the Nod-like receptor protein-3 (NLRP3) and NF-κB gene expression, which plays a notable role in inciting inflammatory pathways.
Thirty-two male Wistar rats were divided into four equal groups: 1) control (Vehicle) group underwent laparotomy and received normal saline. 2) In the SILI group, a laparotomy was performed, and 30 mg/kg silibinin was injected intraperitoneal (IP). 3) I/R group underwent I/R and received normal saline. 4) The I/R + SILI group encountered I/R after laparotomy and received silibinin. After one hour of ischemia and three hours of reperfusion, blood and liver tissue samples were assembled for future biochemical, histological, and gene expression studies.
In vivo analysis attested that serum AST and ALT activities were significantly lessened by silibinin in the SILI + I/R group (P <0.001). Silibinin ameliorated inflammatory liver tissue injuries, including neutrophil and macrophage infiltration, hepatocyte degeneration, cytoplasmic vacuolation, vascular endothelial damages, and sinusoid dilation observed in the I/R group. During I/R, the NLRP3 and NF-κB gene expression owned a significant increment compared to the control group (P <0.001), which could alleviate by silibinin (P <0.01).
The results declared that adjusting the expression of NLRP3 and NF-κB genes during I/R is probably one of the mechanisms of the anti-inflammatory effects of silibinin.
Keywords: Ischemia, NF-κB, NLRP3, Reperfusion, Silibinin.
- Keywords: Ischemia, NF-κB, NLRP3, Reperfusion, Silibinin.
1. Konishi T, Lentsch AB. Hepatic ischemia/reperfusion: mechanisms of tissue injury, repair, and regeneration. Gene Expression The Journal of Liver Research. 2017;17(4):277-87.
2. Freitas SH, Doria RG, Bueno RS, Rocha WB, Filho JR, Moraes JR, et al. Evaluation of potential changes in liver and lung tissue of rats in an ischemia-reperfusion injury model (modified pringle maneuver). PLoS One. 2017;12(6):e0178665.
3. Miah MK, Bickel U, Mehvar R. Effects of hepatic ischemia-reperfusion injury on the blood-brain barrier permeability to [14 C] and [13 C] sucrose. Metabolic Brain Disease. 2017;32(6):1903-12.
4. Jochmans I, Meurisse N, Neyrinck A, Verhaegen M, Monbaliu D, Pirenne J. Hepatic ischemia/reperfusion injury associates with acute kidney injury in liver transplantation: prospective cohort study. Liver Transplantation. 2017;23(5):634-44.
5. van Golen RF, Reiniers MJ, Marsman G, Alles LK, van Rooyen DM, Petri B, et al. The damage-associated molecular pattern HMGB1 is released early after clinical hepatic ischemia/reperfusion. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2019;1865(6):1192-200.
6. Wu Y, Zhang W, Li M, Cao D, Yang X, Gong J. Nobiletin ameliorates ischemia–reperfusion injury by suppressing the function of Kupffer cells after liver transplantation in rats. Biomedicine & Pharmacotherapy. 2017;89:732-41.
7. Li S-p, Wang F-f, Zhang W-k, Bian M-z, Zhang S-y, Yan H, et al. Characteristics of Changes in Inflammatory Cytokines as a Function of Hepatic Ischemia-Reperfusion Injury Stage in Mice. Inflammation. 2019;42(6):2139-47.
8. Abazari O, Divsalar A, Ghobadi R. Inhibitory effects of oxali-Platin as a chemotherapeutic drug on the function and structure of bovine liver catalase. Journal of Biomolecular Structure and Dynamics. 2020;38(2):609-15.
9. Li J, Li R, Lv G, Liu H. The mechanisms and strategies to protect from hepatic ischemia-reperfusion injury. Eur Rev Med Pharmacol Sci. 2015;19(11):2036-47.
10. de Zoete MR, Palm NW, Zhu S, Flavell RA. Inflammasomes. Cold Spring Harbor perspectives in biology. 2014;6(12):a016287.
11. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nature Reviews Immunology. 2016;16(7):407-20.
12. Bortolotti P, Faure E, Kipnis E. Inflammasomes in tissue damages and immune disorders after trauma. Frontiers in immunology. 2018;9:1900.
13. Jo E-K, Kim JK, Shin D-M, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cellular & molecular immunology. 2016;13(2):148-59.
14. Asadi A, Nezhad DY, Javazm AR, Khanicheragh P, Mashouri L, Shakeri F, et al. In vitro Effects of Curcumin on Transforming Growth Factor-β-mediated Non-Smad Signaling Pathway, Oxidative Stress, and Pro‐inflammatory Cytokines Production with Human Vascular Smooth Muscle Cells. Iranian Journal of Allergy, Asthma and Immunology. 2019:1-10.
15. Kim HY, Kim SJ, Lee SM. Activation of NLRP 3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/reperfusion. The FEBS journal. 2015;282(2):259-70.
16. Wang L, Li N, Lin D, Zang Y. Curcumin protects against hepatic ischemia/reperfusion induced injury through inhibiting TLR4/NF-κB pathway. Oncotarget. 2017;8(39):65414.
17. Patel P, Drayman N, Liu P, Bilgic M, Tay S. Deep learning reveals hidden variables underlying NF-κB activation in single cells. bioRxiv. 2019:687848.
18. Afonina IS, Zhong Z, Karin M, Beyaert R. Limiting inflammation—the negative regulation of NF-κB and the NLRP3 inflammasome. Nature immunology. 2017;18(8):861.
19. Boaru SG, Borkham-Kamphorst E, Van de Leur E, Lehnen E, Liedtke C, Weiskirchen R. NLRP3 inflammasome expression is driven by NF-κB in cultured hepatocytes. Biochemical and biophysical research communications. 2015;458(3):700-6.
20. Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam M, Ghalandari B, Saboury AA, et al. Interaction of the synthesized anticancer compound of the methyl-glycine 1, 10-phenanthroline platinum nitrate with human serum albumin and human hemoglobin proteins by spectroscopy methods and molecular docking. Journal of the Iranian Chemical Society. 2020:1-14.
21. Akbari-Kordkheyli V, Azizi S, Khonakdar-Tarsi A. Effects of Silibinin on hepatic warm ischemia-reperfusion injury in the rat model. Iranian Journal of Basic Medical Sciences. 2019;22(7):789.
22. Qajari NM, Shafaroudi MM, Gholami M, Khonakdar-Tarsi A. Silibinin treatment results in reducing OPA1&MFN1 genes expression in a rat model hepatic ischemia–reperfusion. Molecular Biology Reports. 2020:1-10.
23. Zhu X-X, Ding Y-H, Wu Y, Qian L-Y, Zou H, He Q. Silibinin: a potential old drug for cancer therapy. Expert review of clinical pharmacology. 2016;9(10):1323-30.
24. Yang N, Jia X, Wang D, Wei C, He Y, Chen L, et al. Silibinin as a natural antioxidant for modifying polysulfone membranes to suppress hemodialysis-induced oxidative stress. Journal of Membrane Science. 2019;574:86-99.
25. Tajmohammadi A, Razavi BM, Hosseinzadeh H. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review. Phytotherapy research. 2018;32(10):1933-49.
26. Chen Y-H, Lin H, Wang Q, Hou J-W, Mao Z-J, Li Y-G. Protective role of Silibinin against myocardial ischemia/reperfusion injury-induced cardiac dysfunction. International Journal of Biological Sciences. 2020;16(11):1972.
27. Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam M, Ghalandari B, Saboury AA. Probing the biological evaluations of a new designed Pt (II) complex using spectroscopic and theoretical approaches: Human hemoglobin as a target. Journal of Biomolecular Structure and Dynamics. 2016;34(5):1123-31.
28. Chen Z, Ding T, Ma C-G. Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by suppressing inflammation and oxidative stress in NLRC5 deficient mice. Biochemical and Biophysical Research Communications. 2017;493(2):1143-50.
29. Olthof PB, van Golen RF, Meijer B, van Beek AA, Bennink RJ, Verheij J, et al. Warm ischemia time-dependent variation in liver damage, inflammation, and function in hepatic ischemia/reperfusion injury. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2017;1863(2):375-85.
30. Cannistrà M, Ruggiero M, Zullo A, Gallelli G, Serafini S, Maria M, et al. Hepatic ischemia reperfusion injury: A systematic review of literature and the role of current drugs and biomarkers. International journal of surgery. 2016;33:S57-S70.
31. Shafaei Z, Abazari O, Divsalar A, Ghalandari B, Poursoleiman A, Saboury AA, et al. Effect of a Synthesized Amyl-Glycine1, 10-Phenanthroline Platinum Nitrate on Structure and Stability of Human Blood Carrier Protein, Albumin: Spectroscopic and Modeling Approaches. Journal of fluorescence. 2017;27(5):1829-38.
32. Inoue Y, Shirasuna K, Kimura H, Usui F, Kawashima A, Karasawa T, et al. NLRP3 regulates neutrophil functions and contributes to hepatic ischemia–reperfusion injury independently of inflammasomes. The Journal of Immunology. 2014;192(9):4342-51.
33. Guo Z, Yu S, Chen X, Ye R, Zhu W, Liu X. NLRP3 is involved in ischemia/reperfusion injury. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 2016;15(6):699-712.
34. Serasanambati M, Chilakapati SR. Function of nuclear factor kappa B (NF-kB) in human diseases-a review. South Indian Journal of Biological Sciences. 2016;2(4):368-87.
35. Huang H, Tohme S, Al‐Khafaji AB, Tai S, Loughran P, Chen L, et al. Damage‐associated molecular pattern–activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology. 2015;62(2):600-14.
36. Sadatomo A, Inoue Y, Ito H, Karasawa T, Kimura H, Watanabe S, et al. Interaction of neutrophils with macrophages promotes IL-1β maturation and contributes to hepatic ischemia–reperfusion injury. The Journal of Immunology. 2017;199(9):3306-15.
37. He Q, Li Z, Wang Y, Hou Y, Li L, Zhao J. Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhibiting NLRP3 inflammasome activation through Sirt1-dependent autophagy induction. International immunopharmacology. 2017;50:208-15.
38. Lingappan K. NF-κB in oxidative stress. Current opinion in toxicology. 2018;7:81-6.
39. Kim B-R, Seo H-S, Ku J-M, Kim G-J, Jeon CY, Park JH, et al. Silibinin inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling pathway in HMC-1 human mast cells. Inflammation Research. 2013;62(11):941-50.
40. Zhang B, Wang B, Cao S, Wang Y, Wu D. Silybin attenuates LPS-induced lung injury in mice by inhibiting NF-κB signaling and NLRP3 activation. International Journal of Molecular Medicine. 2017;39(5):1111-8.
41. Matias ML, Gomes VJ, Romao-Veiga M, Ribeiro VR, Nunes PR, Romagnoli GG, et al. Silibinin downregulates the NF-κB pathway and NLRP1/NLRP3 inflammasomes in monocytes from pregnant women with preeclampsia. Molecules. 2019;24(8):1548.
- Abstract Viewed: 0 times